Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Promisemed Hangzhou Meditech CoBJSE:920069 18 EBITDA Margin % is 27.57% as of Jun. 2026, which is 24% below its 10-year median of 36.11. GuruFocus rates BJSE:920069 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, Promisemed Hangzhou Meditech Co ranks worse than 72.52% on this metric.
Promisemed Hangzhou Meditech Co (BJSE:920069) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Promisemed Hangzhou Meditech Co EBITDA Margin % Related Terms
Promisemed Hangzhou Meditech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Promisemed Hangzhou Meditech Co EBITDA Margin % Chart
BJSE:920069 vs ISRG, BDX, RMD: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Promisemed Hangzhou Meditech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Promisemed Hangzhou Meditech Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Promisemed Hangzhou Meditech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Promisemed Hangzhou Meditech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Promisemed Hangzhou Meditech Co (BJSE:920069) has a EBITDA Margin % of 27.57% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Promisemed Hangzhou Meditech Co and its competitors. This is 24% below median its historical median of 36.11. According to the industry distribution chart, Promisemed Hangzhou Meditech Co ranks #591 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 72.5%.
Is Promisemed Hangzhou Meditech Co's EBITDA Margin % too high?
Promisemed Hangzhou Meditech Co's current EBITDA Margin % of 27.57% is 24% below median its 10-year median of 36.11. The Medical Devices & Instruments industry median EBITDA Margin % is 8.06. Promisemed Hangzhou Meditech Co's value of 27.57% is 242.1% above this industry median. Based on the distribution chart, Promisemed Hangzhou Meditech Co ranks #591 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Promisemed Hangzhou Meditech Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Promisemed Hangzhou Meditech Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Promisemed Hangzhou Meditech Co ranks #591 out of 815 companies for EBITDA Margin %. This places Promisemed Hangzhou Meditech Co in the lower half of its industry. The industry median EBITDA Margin % is 8.06. Promisemed Hangzhou Meditech Co's value of 27.57% is 242.1% above this benchmark. While the company's 10-year median is 36.11 vs. the industry median of 8.06, Promisemed Hangzhou Meditech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 8.06, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Promisemed Hangzhou Meditech Co's current EBITDA Margin % of 27.57% is 242.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Promisemed Hangzhou Meditech Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 8.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Promisemed Hangzhou Meditech Co's current EBITDA Margin % is 27.57%, which is 24% below median its own 10-year median of 36.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Promisemed Hangzhou Meditech Co stock overvalued right now?
Promisemed Hangzhou Meditech Co (BJSE:920069) has a current EBITDA Margin % of 27.57%. The current EBITDA Margin % is 27.57%, which is 24% below median its 10-year median of 36.11 and 242.1% above the Medical Devices & Instruments industry median of 8.06. Promisemed Hangzhou Meditech Co's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Promisemed Hangzhou Meditech Co (BJSE:920069), the current EBITDA Margin % is 27.57% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Promisemed Hangzhou Meditech Co Ltd is engaged in the Research, development, production and sales of diabetes care, universal drug delivery and infusion, and minimally invasive interventional medical devices.
18GF Score
Get the complete analysis for BJSE:920069
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920069 has been successfully added to your 
